## Drug Summary
Bosutinib, sold under the brand name Bosulif, is an anticancer medication belonging to the class of tyrosine kinase inhibitors (TKIs). It is primarily used in the treatment of chronic myelogenous leukemia (CML), particularly in patients who are resistant or intolerant to previous therapy, such as treatment with imatinib. Bosutinib specifically targets the BCR-ABL tyrosine kinase, a fusion protein resulting from the Philadelphia chromosome abnormality in CML. The drug inhibits the kinase activity, thereby blocking the proliferation and survival pathways of the leukemic cells. Bosutinib is administered orally and exhibits metabolism predominantly through the liver, primarily via cytochrome P450 3A4 (CYP3A4), with its pharmacokinetics showing variability influenced by hepatic enzyme levels.

## Drug Targets, Enzymes, Transporters, and Carriers
As a kinase inhibitor, bosutinib's primary target is the BCR-ABL tyrosine kinase. It inhibits this kinase by binding to the ATP-binding pocket, thus preventing phosphorylation and subsequent activation of downstream signaling pathways crucial for cancer cell growth and survival. Additionally, bosutinib shows inhibition towards other tyrosine kinases such as SRC family kinases, which may contribute to its therapeutic effect and side profile. The drug's metabolism involves primarily the CYP3A4 isoenzyme in the liver, and it's susceptible to interactions with drugs that induce or inhibit CYP3A4. Details on specific transporters and carriers are not explicitly mentioned but would typically involve those common in drug excretion and distribution, such as P-glycoprotein (P-gp) and other ATP-binding cassette (ABC) transporters.

## Pharmacogenetics
Pharmacogenetic aspects of bosutinib treatment involve primarily the influence of CYP3A4 enzyme variations, which can alter drug metabolism rates significantly. Patients with certain polymorphisms in the CYP3A4 gene might experience different exposure levels to bosutinib, affecting both efficacy and toxicity. For instance, individuals with CYP3A4*1G variant might have reduced enzyme activity leading to higher plasma levels of bosutinib, potentially increasing the risk of adverse effects. Similarly, genetic variations in drug transporters like ABCB1, which encodes P-gp, could influence the absorption and disposition of the drug, impacting therapy outcomes. Clinical guidelines recommend considering genetic testing for key metabolizing enzymes and transporters in the context of adverse reactions or unexpected therapeutic failures. However, more extensive population-specific studies are needed to fully integrate these genetic factors into routine clinical practice for bosutinib dosing and management.